Risk factors for the development of pedal edema in patients using pramipexole

Archives of Neurology

Volumn 64, Issue 6, 2007, Pages 820-824

  Kleiner Fisman, Galit ^a,c   Fisman, David N ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BROMOCRIPTINE MESILATE; CALCIUM CHANNEL BLOCKING AGENT; ENTACAPONE; FLUDROCORTISONE ACETATE; LEVODOPA; PERGOLIDE MESILATE; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; AGGRESSION; ARTICLE; BIVARIATE ANALYSIS; COGNITIVE DEFECT; COMORBIDITY; CONFIDENCE INTERVAL; CONFUSION; CORONARY ARTERY DISEASE; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG WITHDRAWAL; FATIGUE; FOOT EDEMA; HALLUCINATION; HUMAN; HYPERSEXUALITY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; NERVOUSNESS; OUTCOME ASSESSMENT; PARESTHESIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSYCHOSIS; RASH; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SYNCOPE;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; DOPAMINE AGONISTS; EDEMA; FOOT DISEASES; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MEDICAL RECORDS; MIDDLE AGED; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 34250349125     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.6.noc60158     Document Type: Article

References (20)

1. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044-1053.
2. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA. 2000;284:1931-1938.
3. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162-168.
4. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease: the Pramipexole Study Group. Neurology. 1997;49:724-728.
5. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the nonergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999;66:436-441.
6. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72:713-720.
7. Möller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord. 2005;20:602-610.
8. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease: International Pramipexole-Bromocriptine Study Group. Neurology. 1997;49:1060-1065.
9. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol. 1995;18:338-347.
10. Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. Parkinson Study Group. JAMA. 1997;278:125-130.
11. Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol. 2000;57:729-732.
12. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord. 2004;19:22-28.
13. Woodward M. Modelling binary outcome data. In: Epidemiology: Study Design and Data Analysis. 2nd ed. Boca Raton, Fla: Chapman and Hall/CRC; 2005:515-600.
14. Woodward M. Modelling follow-up data. In: Epidemiology: Study Design and Data Analysis. 2nd ed. Boca Raton, Fla: Chapman and Hall/CRC; 2005:601-671.
15. Kim MY, Goldberg JD. The effects of outcome misclassification and measurement error on the design and analysis of therapeutic equivalence trials. Stat Med. 2001;20:2065-2078.
16. Messiaen T, Lefebvre C, Weynand B, Pieters T. Pleural effusion and severe edema of the lower limbs induced by bromocriptine [in French]. Rev Med Interne. 1996;17:680-683.
17. Bianchi M, Castiglioni MG. Refractory generalized edema: an infrequent complication of long-term pergolide treatment for Parkinson disease. Clin Neuropharmacol. 2005;28:245-246.
18. Blackard WG. Edema - an infrequently recognized complication of bromocriptine and other ergot dopaminergic drugs. Am J Med. 1993;94:445.
19. Varsano S, Gershman M, Hamaoui E. Pergolide-induced dyspnea, bilateral pleural effusion and peripheral edema. Respiration. 2000;67:580-582.
20. Schrag AE, Brooks DJ, Brunt E, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharmacol. 1998;21:169-175.